Hamlet NEWSLETTER Important steps forward towards treating bladder cancer
We are pleased to inform you that our clinical dose escalation study with the Hamlet peptide drug Alpha1H in patients with bladder cancer was successfully completed in December 2021. The data analysis is ongoing but the preliminary results communicated are very promising indeed.We are also proud that despite the pandemic, we have completed the study on time, emphasizing our commitment to patients and shareholders. This important step on the journey from discovery to a drug puts us closer to the final stages of drug development, before Phase III and FDA approval. Each year around 500